The Fund aims to achieve a high level of monthly income with prospects for capital growth.
Name | % Net Assets |
---|---|
GlaxoSmithKline PLC | 4.5% |
BT Group PLC | 3.8% |
Royal Dutch Shell PLC (CL B) | 3.8% |
AstraZeneca PLC | 3.7% |
Imperial Tobacco Group PLC | 3.1% |
Unilever PLC | 2.9% |
British American Tobacco PLC | 2.7% |
Legal & General Group PLC | 2.2% |
BG Group PLC | 2.1% |
RSA Insurance Group PLC | 2.1% |
Key | % Net Assets |
---|---|
GlaxoSmithKline PLC | 4.5% |
BT Group PLC | 3.8% |
Royal Dutch Shell PLC (CL B) | 3.8% |
AstraZeneca PLC | 3.7% |
Other | 84.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 84.67p |
Currency | GBP |
Change | 0.050p |
% | 0.06% |
YTD change | 3.92p |
YTD % | 4.85% |
Fund Inception | 04/10/1999 |
---|---|
Fund Manager | Chris White / Ketish Pothalingam |
TER | 1.38 (30-Mar-2012) |
Minimum Investment | |
---|---|
Initial | £2000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 3.75% |
Annual Mang't | 1.25% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.16 |
You are here: research